David Woods, MD
Ophthalmology · Chico, CANPI 1225038185
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $95,724 of the $99,731 with a category attached, or 96.0%. Rxsight Inc accounts for 95.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $91,706 and has fallen 99.5% since, to $460 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $1060.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$95K
- NEW World Medical,inc.$2K
- Ivantis, Inc$1K
- Alcon$437
- AbbVie$223
- Aerie Pharmaceuticals, Inc.$180
- plus $573 from 10 others
Across 234 payments — averaging $1182.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$272K
- Ivantis, Inc$3K
- Alcon Research LLC$2K
What the payments were for
- Consulting fees$95,72496%
- Speaking & faculty fees$580%
- Food & beverage$3,8294%
- Gifts$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 12 | $94,963 |
| NEW World Medical,inc. | 19 | $2,055 |
| Ivantis, Inc | 6 | $1,301 |
| Alcon | 18 | $437 |
| AbbVie(2 entities) | 8 | $223 |
| Aerie Pharmaceuticals, Inc. | 4 | $180 |
| Amgen(2 entities) | 8 | $174 |
| Novartis | 6 | $129 |
| Biotissue Holdings Inc. | 6 | $122 |
| Carl Zeiss Meditec, Inc. | 1 | $32 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
| Dompe US, Inc. | 1 | $20 |
| Sight Sciences, Inc. | 1 | $20 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Agiliti Surgical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$91,321
- RXSIGHT INJECTOR HANDPIECE$3,486
- RXSIGHT CONTACT LENS$3,486
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$3,486
- RXSIGHT INJECTOR CARTRIDGE$3,486
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$3,486
- Kahook Dual Blade$1,873
- Ahmed Glaucoma Valve$1,873
- Clearpath$1,707
- Streamline$1,707
- Hydrus Microstent$1,000
- Streamline Surgical System$167
- Hydrus$150
- Rhopressa$119
- Rocklatan$119
- XEN GLAUCOMA TREATMENT SYSTEM$105
How this compares
$99,731 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 253 | $106,391 |
| RhopressaNetarsudil Mesylate | 154 | $82,517 |
| XiidraLifitegrast | 58 | $43,451 |
| RocklatanNetarsudil Mesylat/Latanoprost | 60 | $27,706 |
| Prednisolone Acetate | 893 | $24,890 |
| Travoprost | 52 | $11,517 |
| Latanoprost | 1,246 | $10,544 |
| Ketorolac Tromethamine | 688 | $9,779 |
| Alphagan PBrimonidine Tartrate | 30 | $9,495 |
| IlevroNepafenac | 12 | $8,334 |
| VyzultaLatanoprostene Bunod | 33 | $8,184 |
| Cyclosporine | 21 | $6,259 |
| Timolol Maleate | 659 | $6,218 |
| Brimonidine Tartrate | 230 | $6,129 |
| ProlensaBromfenac Sodium | 13 | $4,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan | $223 | $119,647295 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $180 | $110,223214 claims |
| NovartisIlevro | $129 | $8,33412 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $24 | $4,40513 claims |
| AlconSimbrinza | $437 | $4,24321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Chico
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.